cllsociety.org/2022/08/eha-...
"Conclusion:
Double exposed patients with CLL/SLL don’t do well, as proved by these rather grim statistics on time to next treatment discontinuation, duration of the subsequent therapy, and overall survival. The authors conclude, and we wholeheartedly agree: “There remains a need for more effective therapies for patients with CLL/SLL after progression on cBTKi/BCL2i“."